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Abstract We investigated insulin's effect on intestinal lipid 
transport and, particularly, the biogenesis of apolipoproteins 
crucial to lipoprotein secretion. Adding insulin (3 mU) to the 
serum-free medium of cultured jejunal explants from human 
fetuses (17-20 weeks) reduced triglyceride and chylomicron 
production and inhibited apo B-48 and apo B-100 secretion. 
When apo B mRNA was assayed by RT-PCR and its editing by 
primer extension, no change was detectable following the 
addition of insulin. HDL lipid content, apo A-1 synthesis and 
RNA level were unaffected by insulin. Collectively, these results 
suggest hat the insulin-stimulated ecline in intestinal chylomi- 
cron output may involve apo B co- or post-translational 
modifications. 
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1. Introduction 
Among the most important functions of the intestine is the 
transport of dietary fat in the form of lipoproteins [1]. The 
enterocyte is the unique site for chylomicron formation, but is 
also a source for very-low-density lipoprotein (VLDL) and 
high-density lipoprotein (HDL) production [2,3]. These nas- 
cent lipoproteins contain apoproteins (apo) A-I and B as the 
major protein constituents [1-4]. 
The synthesis and secretion of intestinal and hepatic lipo- 
proteins are exquisitely regulated by several factors, including 
hormones, growth factors and nutrients. Much information 
related to this field has been acquired from studies focusing 
on various animal species. However, our knowledge of the 
regulation of lipid transport in humans, especially at the in- 
testinal level, remains elusive. Recently, we employed the 
model of jejunal organ culture to study the properties, devel- 
opment and regulation of nascent lipoprotein particles [5,6]. 
Our findings demonstrated that human jejunal explants in 
culture retain a few of the normal biochemical functions of 
adult intestine, such as the ability to elaborate complex lipid 
macromolecules a sociated with apoproteins. This efficient lip- 
oprotein-lipid transport proved to be influenced by the devel- 
opmental process and a certain number of hormones [5 7]. In 
particular, the addition of insulin to the culture medium sig- 
nificantly decreased the output of chylomicrons [8]. In this 
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regard, the inhibition of triglyceride secretion by insulin has 
been demonstrated in perfused rat livers, rat hepatocytes and 
HepG2, a human hepatoma cell line [9 12]. 
The aim of this investigation was first to examine the effect 
of insulin on the de novo synthesis of intestinal apoproteins 
A-I and B, and second to determine whether changes in their 
production could be related to the level of apo A-I and apo B 
mRNA.  Finally, the distribution of the two distinct forms of 
apo B (B-100 and B-48) and the molecular mechanism of their 
specific partitioning, referred to as apo B mRNA editing 
[13,14], were evaluated under the action of insulin. 
2. Materials and methods 
2.1. Intestinal specimens and culture conditions 
Tissues from fetuses ranging from 17 to 20 weeks in age were 
obtained from normal elective pregnancy terminations. No tissue 
was collected from cases associated with known fetal abnormality 
or fetal death legal abortion. Studies were approved by the Institu- 
tional Human Subject Review Board. The entire small intestine was 
immersed in Leibovitz L-15 medium (room temperature) containing 
garamycin (40 ~tg/ml) and brought immediately to the culture room. 
The proximal half of the intestine xcluding the first 3 cm was used 
and defined as jejunum. 
The jejunum was cleansed of mesentery, split longitudinally, washed 
in culture medium, and cut into explants (3x 7 mm). Five to seven 
explants were randomly transferred onto lens paper with the mucosal 
side facing up in each organ culture dish (Falcon Plastics, Los An- 
geles, CA). Six dishes were used for each experimental condition. An 
amount of medium (0.8 ml) sufficient o dampen the lens paper was 
added. Explants were cultured in serum-free Leibovitz L-15 medium 
according to the technique described previously [5 8]. After a 3 h 
stabilization period, the medium was changed with a fresh one con- 
taining a final amount of 0.13 ~tmol/ml of unlabeled oleic acid at- 
tached to albumin. The preparation of oleate/albumin complex was 
prepared as detailed previously [5-8]. Insulin was added at concentra- 
tions of 3 mU/ml and intestinal explants were cultured for 42 h. 
2.2. De novo apolipoprotein synthesis." Pulse labeling of intestinal 
explants and immunoprecipitation procedure 
Following the incubation period with unlabeled oleic acid to stimu- 
late the synthesis of apoproteins, jejunal explants were washed twice 
with methionine-free L ibovitz medium. They were, then, incubated in 
the same medium, containing unlabeled oleic acid, for 45 min in the 
presence of [35S]methionine (300 ~Ci/ml) with or without insulin. At 
the end of the labeling period, at 37°C, explants were washed (x 3) 
and homogenized in phosphate-buffered saline (20 mM sodium phos- 
phate, 145 mM NaC1, pH 7.4) containing 1% (w/v) Triton X-100, 
methionine (2 mM), phenylmethylsulfonyl fluoride (1 mM), and ben- 
zamidine (1 mM). Aliquots of tissue homogenates were precipitated 
with 20% trichloroacetic acid), and precipitates were washed three 
times with 5% trichloroacetic acid before the radioactivity was deter- 
mined in a Beckman liquid scintillation spectrometer. The homoge- 
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nates were also centrifuged (4°C) at 105 000 x g for 60 min in a 50-Ti 
rotor (Beckman, CA) and supernatants subsequently reacted with ex- 
cess apoprotein polyclonal antibodies for 18 h at 4°C. The immuno- 
precipitation of apo A-I and apo B was carried out with polyclonal 
antibodies obtained commercially (Boehringer, Quebec, Canada). 
Pansorbin (Calbiochem, CA) was then added, and the mixture was 
reincubated at20°C for 60 min. The immunoprecipitates were washed 
extensively and analyzed by a linear 4-20'70 acrylamide gradient pre- 
ceded by a 3% stacking gel as described previously [7]. Gels were 
sectioned into 4-ram slices and counted after an overnight incubation 
at 20°C with 1 ml BTS-450 (Beckman) and 10 ml of liquid scintillation 
fluid (Ready Solv. NA, Beckman). 
2.3. Sample extraction and RT-PCR analysis 
After incubating explants in the presence or absence of insulin, total 
RNA was isolated as described by Chomczynski and Saccbi [15]. 
Single-strand cDNA was synthesized from the extracted and dena- 
tured RNA (5 min, 65°C) by the reverse transcriptase r action, con- 
sisting of 1 mM dNTP (Pharmacia), 2.5 [aM pd (N)6 (Pharmacia), 200 
U superscript II RNAse H transcriptase (Gibco), 8 U RNAse inhibi- 
tor (Boehringer°Mannheim, Montreal, Canada), 50 mM Tris-HC1 (pH 
8.3), 3 mM MgCI2, 75 mM KC1 and 10 mM DTT. The mixture was 
incubated (10 min) at room temperature and reverse transcription was 
performed at 42°C for 2 h followed by inactivation (70°C for 15 min). 
The PCR amplification was performed in a mixture containing 5 [al 
of reverse transcribed reaction, 10 mM Tris-HCl (pH 8.3), 1.5 mM 
MgC12, 50 mM KCI, 1 [aM of each primer (lower and upper) and 2 U 
Tag DNA polymerase (Boehringer). The amplification of apo B and 
GAPDH was carried out in the same tissue with 30 cycles of dena- 
turation at 94°C for 30 s annealing at 56.3°C for 90 s, and extension 
at 72°C for 60 s, with a final 10 min extension at 72°C. Apo A-I was 
amplified using 25 cycles and annealing at 62°C with the same con- 
ditions as above. PCR products (A-I, 196 bp; B, 238 bp; GAPDH, 
384 bp) were separated with 6% polyacrylamide gel electrophoresis 
and quantified by Phosphorimager (Molecular Dynamics). 
The PCR primers used in this study are: 
Apo A-I : 
ApoB: 
GAPDH: 
minus:5'-CTG TGT ACG TGG ATG TGC-3' 
plus:5'-CCT TCT GTC TCC TTT TCC-3' 
minus:5'-CCT CT GTC TCC TTT TCC-3' 
plus:5'-CAA TCC CAT GTT CTG GAG-3' 
minus:5'-CCC ATC ACC ATC TTC CAG-3' 
plus:5'-CAT CAC GCC ACA GTT TCC-3' 
2.4. Apo B mRNA editing assay 
2.4.1. RNA preparation. Following organ culture technique, ex- 
plants were washed extensively in ice-cold sterile saline, frozen in 
liquid nitrogen and stored at -80°C until processing for RNA extrac- 
tion. RNA was extracted with buffer-saturated phenol/chlorofl~rm 
(1:1), and precipitated at -20°C. To remove contaminating residual 
nuclear DNA, total RNA was treated with RNase-free DNase (Pro- 
mega) for 15 min at 37°C. 
2.4.2. eDNA synthesis. 500 1000 ng total RNA in 10 [al was de- 
natured for 5 min at 65°C and immediately chilled on ice. Following 
the addition of 10 [al of a mixture containing 0.5 mM dNTP (Phar- 
macia), 4 [aM 3'-apo B oligo (5' TTCAATGATATCAATAATA 3'), 
12.5 U AMV reverse transcriptase (Boehringer Mannheim) and 8 U 
RNase inhibitor, a buffer solution (10 mM Tris-HC1 pH 8.3, 1.5 mM 
MgC12 and 50 mM KC) was added. The reverse transcription was 
performed at 42°C for 2 h. 
2.4.3. PCR amplification. PCR amplification was carried out in 50 
111 containing 5 [al reverse transcribed reaction, 10 mM Tris-HC1, pH 
8.3, 1.5 mM MgCI2, 50 mM KC1, 200 [aM dNTP (Pharmacia), 1.6 [aM 
apo B oligo (5' GAGAAACTGACTGCTCTCAC 3'), 2 U Taq DNA 
polymerase, 30 cycles, each consisting of denaturation for 30 s at 
94°C, annealing for 90 s at 54°C and extension for 1 min at 72°C. 
An extension at 72°C for 10 min was added to complete the amplifi- 
cation. PCR product (204 bp) was extracted from agarose gel electro- 
phoresis, precipitated with ethanol and resuspended in 25 [al of sterile 
water. 
2.4.4. Primer extension. Primer extension was performed accord- 
ing to a modification of the technique ofWu et al. [16]. Briefly, 5 [al of 
purified PCR product was denatured at 95°C for 5 rain and kept on 
ice. To this sample was added a mixture (10 [al) containing 67 JaM apo 
B-ext (5' ATC ATA ACT ATC TTT AAT ATA CTG 3'), 0.33 mM 
of each dATP and dCTP (Pharmacia), 0.33 mM ddGTP, 33 ~tM 
dTTP, 15 [aCi [e~-a2P]TTP (NEN, Dupont), 12.5 U AMV reverse 
transcriptase (Boehringer Mannheim), 50 mM Tris pH 8.5, 8 mM 
MgC12, 30 mM KC1, 1 mM DTT. The reaction was carried out at 
42°C for 2 h. Two extension products (33 and 44 nucleotides for 
cDNA unedited and edited apo B mRNA, respectively) were fraction- 
ated on 15% PAGE (acrylamide/bisacrylamide, 19:1). The ratio of 
edited to unedited apo B mRNA was analyzed using a Phosphor- 
imager (Molecular Dynamics). The validation of the primer extension 
and optimization of apo B mRNA editing were verified by controlling 
the critical number of cycles, using serial dilutions of total RNA from 
post-confluent cells and employing known standard amounts of CAA 
and TAA containing products. 
2.5. Analyses 
Lipid and lipoprotein synthesis were also assessed with [14C]oleic 
acid as described previously [5,6]. The tissue homogenate was used for 
protein determinations according to Lowry et al. [17]. 
2.6. Statistical analysis 
Results are reported as means _+ S.E.M. The differences between 
means were assessed using the two-tailed Student's t-test. 
3. Results and discussion 
The mechanisms involved in the regulation of apolipopro- 
teins have been studied extensively in the liver, since (1) this 
organ plays a central role in l ipoprotein synthesis and secre- 
tion as well as in l ipoprotein degradation [4], and (2) numer- 
ous hepatic models are available, including liver slices, per- 
fused livers, hepatoma cells and primary cultures of 
hepatocytes [9 12,18]. Unlike the liver, the small intestine 
was evaluated to a lesser degree in similar functions, probably 
because of the limited number  of models. Considering the 
well-known effects of insulin on protein and lipid synthesis, 
it was of interest o investigate its potential role in modulat ing 
l ipoprotein and apol ipoprotein biogenesis in human intestine. 
Thus, the aim of the current study was to determine the effect 
of insulin on the regulation of lipids, l ipoproteins and apoli- 
poproteins B-100, B-48 and A-I, using human jejunal explants 
cultured in serum-free medium. 
The incorporat ion of [14C]oleic acid into medium and cel- 
lular total lipids and main lipid classes was recorded over a 
period of 42 h. There was a l inear output of neutral ipids and 
phosphol ipids over this period (data not shown). Total lipid 
content and triglycerides, in particular, were much higher in 
media than tissue, demonstrat ing active synthesis and secre- 
tion in cultures of jejunal explants (Fig. 1). Therefore, the 
intestinal organ culture provides a useful in vitro model for 
the investigation of l ipoprotein processing in contrast to the 
limited secretion capacity of Caco-2, a human intestinal 
epithelial cell line, and constitutes a powerful tool to study 
fat transport  mechanisms [19]. The most dramatic effect of 
insulin was the reduction of triglyceride and chylomicron se- 
cretion, confirming and extending our previous findings [8]. 
These observations are in agreement with the inhibitory effects 
of this hormone reported in cultured rat hepatocytes [9-12]. 
The next set of experiments was designed to examine the 
effect of insulin on the process of apol ipoprotein biogenesis. 
Thus, the synthesis of apol ipoproteins by jejunal explants was 
estimated by the incorporat ion of [aSS]methionine. Following 
the incubation, the apol ipoproteins were immunoprecipitated, 
separated by SDS-polyacrylamide gel electrophoresis, identi- 
fied on the basis of electrophoretic mobil ity (compared with 
coelectrophoresed native human plasma apolipoproteins as 
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Fig. l. Effect of insulin on lipid and lipoprotein secretion. After 42 h incubation with [14C]oleic acid in serum-free Leibovitz L-15, in the ab- 
sence and presence of insulin, the medium was recovered and chylomicrons, VLDL and HDL were separated by ultracentrifugation. Lipids 
were extracted, isolated by TLC and their radioactivity counted as described in Section 2. Results of tissue and medium lipids (A,B) as well as 
lipoproteins (C) are expressed as dpm/mg protein in this representative experiment. TG, triacylglycerol; PL, phospholipid; CE, cholesteryl es- 
ter. 
well as stained molecular weight standards) and then counted. 
Fig. 2 shows a representative g l scan, which revealed that the 
jejunal organ culture produced apo A-I as the predominant  
apolipoprotein. In all experiments, apo B-48, of lower molec- 
ular weight, was the major apo B form. Incubat ion of jejunal 
explants in the presence of insulin results in a trend of in- 
creased [35S]methionine incorporat ion into newly synthesized 
apo B (Fig. 2B). However, the addit ion of insulin produced a 
significant decrease in the secretion of apo B-48 and apo B- 
100 (Fig. 2C). On the other hand, insulin had little effect on 
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Fig. 2. Profile of 35S-labeled apolipoproteins A-I and B synthesized by cultured jejunal explants. Following 42 h incubation with unlabeled oleic 
acid in the absence and presence of insulin, jejunal explants were incubated for 45 min with methionine-free medium containing unlabeled oleic 
acid and [35S]methionine with or without insulin. Apolipoproteins were immunoprecipitated and analyzed by SDS-PAGE. Data from a repre- 
sentative xperiment are illustrated in A. Means + S.E.M. (of 10 experiments carried out in triplicates) for tissue and media (expressed as a per- 
cent to total [35S]methionine labeled protein/rag tissue protein) are presented in B and C, respectively. *Results are significantly different from 
the no insulin condition at p < 0.01. 
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Fig. 3. Effect of insulin on apoprotein transcript levels in jejunum explants from 16 19-week-old fetuses. Explants were incubated and mRNA 
determined as indicated in Section 2. (A) Representative effect of insulin on the expression of apolipoproteins. (B) Relative levels (means 
+ S.E.M.) of apolipoprotein mRNA measured in the jejunal explants of 7 individual fetuses (carried out in triplicates) by the technique de- 
scribed in Section 2. Data are expressed as average ratio values of control apo mRNA/control GAPDH mRNA and insulin apo mRNA/insulin 
GAPDH mRNA, GAPDH being the housekeeping gene. 
apo A-I synthesis in parallel with the unchanged production 
of HDL. These results uggest that the observed reduction in 
intestinal triglyceride and chylomicron output in vitro, subse- 
quent to insulin administration, may reflect a direct action of 
insulin on apo B secretion. In similar fashion, the addition of 
insulin to primary cultures of rat hepatocytes resulted in the 
failure of a substantial portion of newly synthesized apo B to 
be secreted [20]. 
In order to determine whether the reduction in apo B synthe- 
sis caused by insulin was related to decreases in intestinal po B 
mRNA, RT-PCR analysis was performed. Interestingly, the 
representative autoradiogram of these gels illustrated in Fig. 
3, as well as the mean of 7 distinct experiments, indicates that 
insulin had no significant effect on the abundance of apo B 
mRNA. Under our experimental conditions, the relative apo 
13 mRNA levels in the presence of insulin were close to con- 
trol values. This suggests that in cultured jejunal explants, the 
expression of the apo B gene is constitutive and that co- or 
post-translational mechanisms may be responsible for the reg- 
ulation of apo B formation. The translational efficiency and 
stability of apo B mRNA may be involved. Intracellular deg- 
radation of apo B has been proposed as a regulatory event 
for VLDL secretion by the liver. Studies in rat hepatocytes 
indicated significant degradation of apo B mediated by insulin 
[21,22]. In agreement, little degradation was noted when in- 
sulin was absent under similar conditions [20]. However, ad- 
ditional investigation is still necessary to assess whether in- 
creased apo B degradation, in the presence of insulin, occurs 
in human intestinal explants. Some workers also stress the 
need to focus on the translational efficiency of apo B 
mRNA transcripts. For example, Adeli and Theriault [23] 
have observed a reduction in apo B synthesis in insulin-treated 
HepG2 lysates, due to a lower translational efficiency of apo B 
mRNA. 
Black and Ellinas [24] have also investigated the effects of 
insulin on apo B synthesis in jejunal explants from newborn 
piglets. No influence of insulin was recorded in these experi- 
ments, suggesting that the modulation of apo B synthesis by 
insulin may depend on both the stage of development and the 
species studied. Consequently, our results may not be directly 
applicable to mature intestinal function. 
Apolipoprotein B is required for the intracellular assembly 
and secretion of triglyceride-rich lipoproteins [20,25]. There 
are two translation products of the apo B gene: human apo 
B-100 is synthesized predominantly by the liver and human 
apo B-48 is produced by the intestine through the newly 
mRNA editing mechanism [13,14]. In our study, the profile 
of apo B mRNA editing was determined by the triplicate 
analysis of separate jejunal explants deriving from 7 fetuses. 
A representative autoradiograph of primer extension products 
isolated from editing reactions is shown in Fig. 4. By 17-20 
weeks of gestation, editing reached a level of 50% UAA. Sim- 
ilar proportions in the ratio of newly synthesized apo B-48 
and apo B-100 were obtained. In contrast, apo B mRNA 
editing was not detectable in triplicate analyses of RNA 
from HepG2 cells used as a negative control. In the human 
intestinal experimental model, we found that the proportion 
of edited apo B mRNA in insulin-treated culture was un- 
changed compared with that of controls. Therefore, insulin, 
unlike other metabolic and hormonal factors in rats, appar- 
ently had no detectable ffect on apo B mRNA editing in 
humans. Thyroid hormone treatment in hypothyroid rats 
[26] and carbohydrate refeeding diet following fasting [27] 
modify the amount of hepatic apo B-48 mRNA. Apo B 
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Fig. 4. Apolipoprotein B mRNA editing detected by RNA primer 
extension analysis in human intestinal explants. The migration of 
non-edited (CAA) and edited (TAA) is shown. Caco-2 and Hep G2 
cells are used as positive and negative controls, respectively. (A) 
Representative r sult from 7 separate experiments. The ratio of 
B-48/B-100 and edited to unedited apo mRNA was determined 
using a Phosphorimager and is presented in B. 
mRNA editing is a developmentally regulated process involv- 
ing apo B expression. In the postnatal rat, swine and human, 
the adult small intestine produces predominantly apo B-48 
because of the activity of this mRNA editing, while editing 
activity is reduced earlier in gestation and increases dramati- 
cally to near adult levels, just before parturition [28,29]. 
In our study, the synthesis of apo A-I was not significantly 
altered in the presence of insulin. In contrast, Masumoto et al. 
[30] reported that higher concentrations of insulin inhibit apo 
A-I production in cultured rat hepatocytes, whereas Elshour- 
bagy et al. [31] observed a 2-fold increase in apo A-I mRNA 
in rat hepatocytes. These contradictory results, however, 
could be due to the use of different models (intestine vs liver) 
and species (humans vs rats). 
It has been suggested that cholesteryl ester (CE), the other 
core lipid of apo B-containing lipoproteins, is a critical reg- 
ulator of apo B secretion [32]. In cultured jejunal explants, 
cholesteryl ester synthesis was limited and unaffected by in- 
sulin. It is likely, therefore, that CE is not an important de- 
terminant in TG-rich lipoprotein secretion, confirming the 
data of Ginsberg's laboratory [33]. 
In summary, insulin caused a significant decrease in chylo- 
micron production, concomitant with a reduction in the secre- 
tion of de novo apo B-100 and apo B-48 synthesis. There were 
no major changes in HDL  lipids or apo A-I. The inhibition of 
apo B output by insulin treatment was not due to altered 
mRNA level. This may implicate possible co- or post-transla- 
tional modification of apo B, resulting in impaired chylomi- 
cron formation. The responsiveness of jejunal explants to the 
257 
addition of insulin provides further evidence for the utility of 
intestinal organ culture in studying the regulation of human 
lipoprotein processing. 
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